12 results about "Infection disease" patented technology

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

This invention relates to the field of biotechnology, and in particular to an antigenic epitope peptide, product, and application for detecting antibodies produced by porcine deltacoronavirus infection. This invention identified short peptide epitopes in PDCoV longitudinal challenge serum samples, obtaining 12 short peptides, which were then prepared into a porcine deltacoronavirus antibody detection kit. Finally, six field serum samples were selected for antibody detection, and the effectiveness was verified using a virus neutralization experiment. The results showed that the porcine deltacoronavirus antibody detection kit provided by this invention is effective. Furthermore, the porcine deltacoronavirus antibody detection kit provided by this invention, as a novel detection method, improves sensitivity and specificity while simultaneously providing multiple detection results, namely, determining whether viral infection has occurred, identifying the stage of infection, and achieving DIVA (Differentiation, Infection, and Variability) analysis.

This invention discloses a one-step RT-PCR method for detecting five viruses in *Calamus sylvestris*, belonging to the field of plant virus molecular detection technology. Specifically, it provides a primer set for the simultaneous detection of multiple viruses in *Calamus sylvestris*, including five pairs of virus-specific primers for the specific detection of PVBV, CaYMAV, CaYMV, CaYSV, and SCMV, and one pair of *Calamus sylvestris* internal reference gene primers, the sequences of which are shown in SEQ ID NO:1-12. RNA is extracted from *Calamus sylvestris* samples, a one-step RT-PCR reaction system is prepared, amplification and electrophoresis are performed, the detection validity is verified by the internal reference gene band, and the type of virus infection is determined by the virus-specific bands. This invention can achieve simultaneous detection of five viruses and has the advantages of simple operation, short detection cycle, high sensitivity, and strong specificity, making it suitable for rapid screening of large batches of *Calamus sylvestris* samples.

This invention relates to the field of infectious disease prevention technology, specifically to an emergency protective shield for infectious diseases, comprising a face mask, straps, and a filter assembly. The filter assembly includes a housing containing a primary filter and a secondary filter. An air outlet is located on the side of the housing near the face mask, and an air inlet is located on the side of the housing away from the face mask. A first cavity and a second cavity are formed within the housing, with their ends connected to the air outlet and air inlet, respectively. The invention allows the filter assembly to be set to a full-efficiency state and a normal state, and this state can be switched back and forth by a switching plate, thus adapting to both high-risk viral environments and everyday environments, allowing the wearer to breathe smoothly in everyday conditions.

This invention relates to the field of medical artificial intelligence technology, and in particular to an AI-assisted diagnostic decision-making system for rare bladder diseases. The system includes modules for data acquisition, feature extraction and quantification, an AI rule-based reasoning engine, error warning, and treatment decision output. Its core lies in using natural language processing technology to transform unstructured clinical text into feature tags. The AI ​​engine then executes a multi-level identification process of "excluding infection – rapid screening of medical history – precise matching," outputting a list of candidate diseases sorted by probability. Simultaneously, the system can automatically warn of clinical errors such as antibiotic abuse and overtreatment, and generate a comprehensive report including primary care treatment plans and referral criteria. This invention combines a rule engine with intelligent reasoning, providing primary care physicians with a standardized and easy-to-use auxiliary diagnostic tool, which helps improve the efficiency and standardization of rare disease diagnosis and has high clinical translational value.

The application belongs to the field of virus culture, and provides a CHO cell, an application, and a virus culture method. In the CHO cell, a gene of bone marrow stromal cell antigen 2 is inactivated. The virus culture method comprises the following steps: (1) constructing the CHO cell in which the gene of bone marrow stromal cell antigen 2 is inactivated, and performing sequencing identification; (2) detecting the proliferation activity of the CHO cell in which the gene of bone marrow stromal cell antigen 2 is inactivated; (3) culturing the CHO cell in which the gene of bone marrow stromal cell antigen 2 is inactivated, and then infecting the virus; and (4) detecting the proliferation of virus nucleic acid and the virus titer. The CHO cell in which the gene of bone marrow stromal cell antigen 2 is knocked out is used to culture and expand the virus, the restriction of the CHO cell on virus budding is released, and the isolation efficiency of the influenza virus and the virus infection titer are improved.

A novel vaccine and methods of preventing and treating C. difficile infection in a patient is described. The vaccine is comprised of a fusion protein (denoted FliCD) comprised of the FliC and FliD from C. difficile and joined by a linker sequence. Administration of the vaccine, as well as anti-FliCD serum, has been shown to prevent C. difficile infection as well as treat existing infections.

The application discloses a living extraction method of citrus Huanglongbing bacteria, relates to the technical field of plant pathogenic bacteria extraction, and solves the problem that the prior art cannot guarantee that the citrus Huanglongbing bacteria have complete biological activity and high purity at the same time. The method comprises four core steps of pretreatment of Rutaceae plant samples, extraction of bacterial liquid, initial enrichment of the bacterial liquid and re-enrichment of the bacterial liquid in sequence, the whole extraction process is carried out in a low-temperature environment, plant tissues infected with pathogenic bacteria are broken by freezing and grinding, and step-by-step extraction and enrichment of the citrus Huanglongbing bacteria are realized by combining step-by-step differential centrifugation and sucrose density gradient centrifugation. The method can effectively retain the complete biological activity of the citrus Huanglongbing bacteria, significantly improve the purity of the bacterial liquid, and the prepared bacterial liquid can be used for infection of healthy Rutaceae plants and microinjection transfection of citrus psyllids, the method is simple in operation and good in repeatability, and provides stable and reliable experimental materials for the research on the pathogenic mechanism, transmission rule and prevention and control technology of the citrus Huanglongbing disease.

The application discloses a chicken MTRF1L protein monoclonal antibody and application thereof, and belongs to the technical field of biotechnology.The MTRF1L recombinant protein is used for immunizing animals, a sensitized B cell with the ability of secreting specific antibodies and a myeloma cell with unlimited reproduction capacity are fused into a B cell hybridoma through a hybridoma technology, and a chicken MTRF1L protein monoclonal antibody is obtained through screening.The application screens a high-quality nucleotide coding sequence of the MTRF1L gene through bioinformatics analysis, and uses the nucleotide coding sequence as an antigen to immunize BABE mice, a sensitized B cell with the ability of secreting specific MTRF1L antibodies and a myeloma cell with unlimited reproduction capacity are fused into a B cell hybridoma through a hybridoma technology, and a positive hybridoma cell is obtained through screening, and the cell supernatant is used for Western Blot and indirect immunofluorescence detection, and it is found that the monoclonal antibody has good specificity and high sensitivity, which lays a foundation for detection of the MTRF1L protein and research on pathological mechanisms of virus infection diseases.

The present application relates to a detection method and kit for distinguishing CAEBV and EBV positive or negative PTCL. The present application provides the use of a detection reagent of a biomarker in the preparation of a composition or kit for distinguishing chronic active Epstein-Barr virus infection (CAEBV), Epstein-Barr virus positive peripheral T cell lymphoma (EBV+ PTCL) and Epstein-Barr virus negative peripheral T cell lymphoma (EBV- PTCL), wherein the biomarker comprises any 1, 2, 3, 4, 5 of the FAS, SELP, LY86, GZMB and CCL7 genes, preferably a combination comprising all 5 of them. Compared with traditional clinical observation, pathological biopsy and in situ hybridization, the present application has higher disease specificity and sensitivity, and can provide molecular basis for early clinical treatment and drug intervention.

This invention discloses a method for constructing an infection diagnostic system. The method includes: storing preprocessed pathological images to generate a pathological image database; processing the pathological images to obtain training set images; constructing a binary classification model for pathological infection regions; and constructing a pathological infection region retrieval model. Correspondingly, another infection diagnostic system constructed using the above method is also provided, as well as an infection diagnostic method using the above infection diagnostic system. This invention achieves a deep integration of artificial intelligence and orthopedic infection pathology, significantly improving the efficiency and accuracy of infection pathology diagnosis.

The application provides a virus in the preparation of bacteriophage, and belongs to the technical field of bacteriophage. The application provides PCV2, phPCV2, PCV3, phPCV3, HEV or phHEV in the preparation of bacteriophage. The application first proposes that eukaryotic viruses can infect bacteria and can replicate in the bacteria, and the viruses show the characteristics of lysogenic bacteriophage. The application has broad spectrum for the infection of the bacteria, can effectively inhibit the reproduction of the bacteria, and has a pioneering significance for developing broad-spectrum bacteriophage bactericides and developing vaccines by using the infection of the viruses on the bacteria. The application can stably amplify the viruses with high toxicity by using Escherichia coli, and the inactivated vaccines prepared by the viruses can significantly protect animals. The application also prepares a RecA-deficient Bacillus subtilis live vector vaccine, so that the virus infection is stably in a lysogenic state for a long time, and the animals are inoculated by oral administration, the animals are colonized in the intestinal tract, and the antigen is continuously expressed to induce a mucosal immune response.